nodes	percent_of_prediction	percent_of_DWPC	metapath
L-DOPA—SLC15A1—Trandolapril—coronary artery disease	0.098	0.176	CbGbCtD
L-DOPA—SLC15A1—Perindopril—coronary artery disease	0.0897	0.161	CbGbCtD
L-DOPA—SLC15A1—Lisinopril—coronary artery disease	0.0743	0.133	CbGbCtD
L-DOPA—SLC15A1—Enalapril—coronary artery disease	0.0743	0.133	CbGbCtD
L-DOPA—SLC15A1—Ramipril—coronary artery disease	0.0743	0.133	CbGbCtD
L-DOPA—SLC15A1—Captopril—coronary artery disease	0.0556	0.0998	CbGbCtD
L-DOPA—CYP2D6—Niacin—coronary artery disease	0.0157	0.0282	CbGbCtD
L-DOPA—CYP2D6—Timolol—coronary artery disease	0.0146	0.0262	CbGbCtD
L-DOPA—CYP2D6—Captopril—coronary artery disease	0.0129	0.0231	CbGbCtD
L-DOPA—CYP2D6—Simvastatin—coronary artery disease	0.0124	0.0223	CbGbCtD
L-DOPA—CYP2D6—Lovastatin—coronary artery disease	0.0122	0.0218	CbGbCtD
L-DOPA—CYP2D6—Pravastatin—coronary artery disease	0.0122	0.0218	CbGbCtD
L-DOPA—CYP2D6—Atorvastatin—coronary artery disease	0.0111	0.0199	CbGbCtD
L-DOPA—PSIP1—cardiac ventricle—coronary artery disease	0.00151	0.163	CbGeAlD
L-DOPA—PSIP1—myocardium—coronary artery disease	0.00142	0.153	CbGeAlD
L-DOPA—Mimosine—CCL2—coronary artery disease	0.00139	0.213	CrCbGaD
L-DOPA—PSIP1—heart—coronary artery disease	0.000991	0.107	CbGeAlD
L-DOPA—PSIP1—cardiovascular system—coronary artery disease	0.000935	0.101	CbGeAlD
L-DOPA—Melphalan—SLC22A3—coronary artery disease	0.00089	0.136	CrCbGaD
L-DOPA—DRD4—heart—coronary artery disease	0.000825	0.089	CbGeAlD
L-DOPA—PSIP1—blood—coronary artery disease	0.000739	0.0798	CbGeAlD
L-DOPA—SLC7A8—heart—coronary artery disease	0.000653	0.0705	CbGeAlD
L-DOPA—SLC7A5—heart—coronary artery disease	0.000506	0.0546	CbGeAlD
L-DOPA—Isoprenaline—MAPK1—coronary artery disease	0.000492	0.0752	CrCbGaD
L-DOPA—SLC7A5—cardiovascular system—coronary artery disease	0.000477	0.0515	CbGeAlD
L-DOPA—SLC7A5—cardiac atrium—coronary artery disease	0.000433	0.0467	CbGeAlD
L-DOPA—SLC7A5—blood—coronary artery disease	0.000378	0.0408	CbGeAlD
L-DOPA—Isoetarine—ADRB1—coronary artery disease	0.000353	0.054	CrCbGaD
L-DOPA—Aminosalicylic Acid—MPO—coronary artery disease	0.000328	0.0501	CrCbGaD
L-DOPA—Isoetarine—ADRB2—coronary artery disease	0.000297	0.0454	CrCbGaD
L-DOPA—SLC16A10—blood—coronary artery disease	0.000289	0.0312	CbGeAlD
L-DOPA—Mesalazine—MPO—coronary artery disease	0.000257	0.0393	CrCbGaD
L-DOPA—Norepinephrine—SLC22A3—coronary artery disease	0.00025	0.0382	CrCbGaD
L-DOPA—Dopamine—SLC22A3—coronary artery disease	0.000232	0.0355	CrCbGaD
L-DOPA—Mesalazine—PPARG—coronary artery disease	0.000229	0.0349	CrCbGaD
L-DOPA—Droxidopa—ADRB1—coronary artery disease	0.000161	0.0247	CrCbGaD
L-DOPA—Dopamine—HTR7—coronary artery disease	0.000147	0.0225	CrCbGaD
L-DOPA—Isoprenaline—ADRB1—coronary artery disease	0.000147	0.0224	CrCbGaD
L-DOPA—Norepinephrine—ADRB1—coronary artery disease	0.000136	0.0208	CrCbGaD
L-DOPA—Droxidopa—ADRB2—coronary artery disease	0.000136	0.0208	CrCbGaD
L-DOPA—Dopamine—ADRB1—coronary artery disease	0.000126	0.0193	CrCbGaD
L-DOPA—Isoprenaline—ADRB2—coronary artery disease	0.000123	0.0189	CrCbGaD
L-DOPA—Epinephrine—ADRB1—coronary artery disease	0.000123	0.0188	CrCbGaD
L-DOPA—Aminosalicylic Acid—PTGS2—coronary artery disease	0.000123	0.0188	CrCbGaD
L-DOPA—Epinephrine—TNF—coronary artery disease	0.000117	0.0179	CrCbGaD
L-DOPA—Norepinephrine—ADRB2—coronary artery disease	0.000114	0.0175	CrCbGaD
L-DOPA—CYP2D6—blood—coronary artery disease	0.00011	0.0119	CbGeAlD
L-DOPA—Epinephrine—ADRB2—coronary artery disease	0.000104	0.0158	CrCbGaD
L-DOPA—Mesalazine—PTGS2—coronary artery disease	9.65e-05	0.0148	CrCbGaD
L-DOPA—Dopamine—CYP2C19—coronary artery disease	9.14e-05	0.014	CrCbGaD
L-DOPA—Rash—Lovastatin—coronary artery disease	8.96e-05	0.000333	CcSEcCtD
L-DOPA—Dermatitis—Lovastatin—coronary artery disease	8.95e-05	0.000332	CcSEcCtD
L-DOPA—Anaemia—Lisinopril—coronary artery disease	8.94e-05	0.000332	CcSEcCtD
L-DOPA—Dyspepsia—Losartan—coronary artery disease	8.94e-05	0.000332	CcSEcCtD
L-DOPA—Feeling abnormal—Perindopril—coronary artery disease	8.92e-05	0.000331	CcSEcCtD
L-DOPA—Headache—Lovastatin—coronary artery disease	8.9e-05	0.000331	CcSEcCtD
L-DOPA—Pruritus—Valsartan—coronary artery disease	8.88e-05	0.00033	CcSEcCtD
L-DOPA—Dry mouth—Ramipril—coronary artery disease	8.88e-05	0.00033	CcSEcCtD
L-DOPA—Chest pain—Timolol—coronary artery disease	8.88e-05	0.00033	CcSEcCtD
L-DOPA—Vomiting—Ezetimibe—coronary artery disease	8.86e-05	0.000329	CcSEcCtD
L-DOPA—Hypersensitivity—Pravastatin—coronary artery disease	8.85e-05	0.000329	CcSEcCtD
L-DOPA—Gastrointestinal pain—Perindopril—coronary artery disease	8.85e-05	0.000329	CcSEcCtD
L-DOPA—Anxiety—Timolol—coronary artery disease	8.85e-05	0.000329	CcSEcCtD
L-DOPA—Angioedema—Lisinopril—coronary artery disease	8.84e-05	0.000328	CcSEcCtD
L-DOPA—Pruritus—Olmesartan—coronary artery disease	8.84e-05	0.000328	CcSEcCtD
L-DOPA—Decreased appetite—Losartan—coronary artery disease	8.83e-05	0.000328	CcSEcCtD
L-DOPA—Abdominal pain—Captopril—coronary artery disease	8.81e-05	0.000327	CcSEcCtD
L-DOPA—Dizziness—Simvastatin—coronary artery disease	8.79e-05	0.000326	CcSEcCtD
L-DOPA—Rash—Ezetimibe—coronary artery disease	8.79e-05	0.000326	CcSEcCtD
L-DOPA—Dermatitis—Ezetimibe—coronary artery disease	8.78e-05	0.000326	CcSEcCtD
L-DOPA—Confusional state—Ramipril—coronary artery disease	8.78e-05	0.000326	CcSEcCtD
L-DOPA—Discomfort—Timolol—coronary artery disease	8.77e-05	0.000326	CcSEcCtD
L-DOPA—Asthenia—Niacin—coronary artery disease	8.76e-05	0.000325	CcSEcCtD
L-DOPA—Fatigue—Losartan—coronary artery disease	8.75e-05	0.000325	CcSEcCtD
L-DOPA—Headache—Ezetimibe—coronary artery disease	8.73e-05	0.000324	CcSEcCtD
L-DOPA—Malaise—Lisinopril—coronary artery disease	8.72e-05	0.000324	CcSEcCtD
L-DOPA—Oedema—Ramipril—coronary artery disease	8.71e-05	0.000323	CcSEcCtD
L-DOPA—Dry mouth—Timolol—coronary artery disease	8.68e-05	0.000322	CcSEcCtD
L-DOPA—Constipation—Losartan—coronary artery disease	8.68e-05	0.000322	CcSEcCtD
L-DOPA—Pain—Losartan—coronary artery disease	8.68e-05	0.000322	CcSEcCtD
L-DOPA—Syncope—Lisinopril—coronary artery disease	8.67e-05	0.000322	CcSEcCtD
L-DOPA—Vomiting—Eplerenone—coronary artery disease	8.67e-05	0.000322	CcSEcCtD
L-DOPA—Feeling abnormal—Furosemide—coronary artery disease	8.67e-05	0.000322	CcSEcCtD
L-DOPA—Leukopenia—Lisinopril—coronary artery disease	8.66e-05	0.000322	CcSEcCtD
L-DOPA—Nausea—Fenofibrate—coronary artery disease	8.64e-05	0.000321	CcSEcCtD
L-DOPA—Pruritus—Niacin—coronary artery disease	8.64e-05	0.000321	CcSEcCtD
L-DOPA—Asthenia—Pravastatin—coronary artery disease	8.62e-05	0.00032	CcSEcCtD
L-DOPA—Gastrointestinal pain—Furosemide—coronary artery disease	8.6e-05	0.00032	CcSEcCtD
L-DOPA—Rash—Eplerenone—coronary artery disease	8.6e-05	0.000319	CcSEcCtD
L-DOPA—Urticaria—Perindopril—coronary artery disease	8.6e-05	0.000319	CcSEcCtD
L-DOPA—Hypersensitivity—Trandolapril—coronary artery disease	8.6e-05	0.000319	CcSEcCtD
L-DOPA—Dermatitis—Eplerenone—coronary artery disease	8.59e-05	0.000319	CcSEcCtD
L-DOPA—Diarrhoea—Valsartan—coronary artery disease	8.59e-05	0.000319	CcSEcCtD
L-DOPA—Confusional state—Timolol—coronary artery disease	8.58e-05	0.000319	CcSEcCtD
L-DOPA—Shock—Ramipril—coronary artery disease	8.56e-05	0.000318	CcSEcCtD
L-DOPA—Hypersensitivity—Enalapril—coronary artery disease	8.56e-05	0.000318	CcSEcCtD
L-DOPA—Abdominal pain—Perindopril—coronary artery disease	8.56e-05	0.000318	CcSEcCtD
L-DOPA—Palpitations—Lisinopril—coronary artery disease	8.55e-05	0.000317	CcSEcCtD
L-DOPA—Diarrhoea—Olmesartan—coronary artery disease	8.55e-05	0.000317	CcSEcCtD
L-DOPA—Headache—Eplerenone—coronary artery disease	8.55e-05	0.000317	CcSEcCtD
L-DOPA—Thrombocytopenia—Ramipril—coronary artery disease	8.52e-05	0.000317	CcSEcCtD
L-DOPA—Oedema—Timolol—coronary artery disease	8.51e-05	0.000316	CcSEcCtD
L-DOPA—Pruritus—Pravastatin—coronary artery disease	8.5e-05	0.000316	CcSEcCtD
L-DOPA—Loss of consciousness—Lisinopril—coronary artery disease	8.5e-05	0.000316	CcSEcCtD
L-DOPA—Nausea—Clopidogrel—coronary artery disease	8.5e-05	0.000316	CcSEcCtD
L-DOPA—Vomiting—Simvastatin—coronary artery disease	8.45e-05	0.000314	CcSEcCtD
L-DOPA—Hypersensitivity—Telmisartan—coronary artery disease	8.45e-05	0.000314	CcSEcCtD
L-DOPA—Cough—Lisinopril—coronary artery disease	8.44e-05	0.000313	CcSEcCtD
L-DOPA—Nausea—Lovastatin—coronary artery disease	8.44e-05	0.000313	CcSEcCtD
L-DOPA—Hyperhidrosis—Ramipril—coronary artery disease	8.42e-05	0.000313	CcSEcCtD
L-DOPA—Rash—Simvastatin—coronary artery disease	8.38e-05	0.000311	CcSEcCtD
L-DOPA—Dermatitis—Simvastatin—coronary artery disease	8.37e-05	0.000311	CcSEcCtD
L-DOPA—Asthenia—Trandolapril—coronary artery disease	8.37e-05	0.000311	CcSEcCtD
L-DOPA—Shock—Timolol—coronary artery disease	8.37e-05	0.000311	CcSEcCtD
L-DOPA—Feeling abnormal—Losartan—coronary artery disease	8.37e-05	0.000311	CcSEcCtD
L-DOPA—Urticaria—Furosemide—coronary artery disease	8.36e-05	0.00031	CcSEcCtD
L-DOPA—Diarrhoea—Niacin—coronary artery disease	8.35e-05	0.00031	CcSEcCtD
L-DOPA—Asthenia—Enalapril—coronary artery disease	8.34e-05	0.00031	CcSEcCtD
L-DOPA—Headache—Simvastatin—coronary artery disease	8.33e-05	0.000309	CcSEcCtD
L-DOPA—Abdominal pain—Furosemide—coronary artery disease	8.32e-05	0.000309	CcSEcCtD
L-DOPA—Gastrointestinal pain—Losartan—coronary artery disease	8.3e-05	0.000308	CcSEcCtD
L-DOPA—Dizziness—Valsartan—coronary artery disease	8.3e-05	0.000308	CcSEcCtD
L-DOPA—Anorexia—Ramipril—coronary artery disease	8.3e-05	0.000308	CcSEcCtD
L-DOPA—Nausea—Ezetimibe—coronary artery disease	8.28e-05	0.000307	CcSEcCtD
L-DOPA—Dizziness—Olmesartan—coronary artery disease	8.26e-05	0.000307	CcSEcCtD
L-DOPA—Pruritus—Trandolapril—coronary artery disease	8.26e-05	0.000307	CcSEcCtD
L-DOPA—Chest pain—Lisinopril—coronary artery disease	8.24e-05	0.000306	CcSEcCtD
L-DOPA—Hyperhidrosis—Timolol—coronary artery disease	8.23e-05	0.000306	CcSEcCtD
L-DOPA—Asthenia—Telmisartan—coronary artery disease	8.23e-05	0.000305	CcSEcCtD
L-DOPA—Pruritus—Enalapril—coronary artery disease	8.22e-05	0.000305	CcSEcCtD
L-DOPA—Diarrhoea—Pravastatin—coronary artery disease	8.22e-05	0.000305	CcSEcCtD
L-DOPA—Anxiety—Lisinopril—coronary artery disease	8.21e-05	0.000305	CcSEcCtD
L-DOPA—Discomfort—Lisinopril—coronary artery disease	8.14e-05	0.000302	CcSEcCtD
L-DOPA—Hypotension—Ramipril—coronary artery disease	8.13e-05	0.000302	CcSEcCtD
L-DOPA—Anorexia—Timolol—coronary artery disease	8.11e-05	0.000301	CcSEcCtD
L-DOPA—Pruritus—Telmisartan—coronary artery disease	8.11e-05	0.000301	CcSEcCtD
L-DOPA—Nausea—Eplerenone—coronary artery disease	8.1e-05	0.000301	CcSEcCtD
L-DOPA—Dizziness—Niacin—coronary artery disease	8.07e-05	0.0003	CcSEcCtD
L-DOPA—Urticaria—Losartan—coronary artery disease	8.07e-05	0.0003	CcSEcCtD
L-DOPA—Dry mouth—Lisinopril—coronary artery disease	8.05e-05	0.000299	CcSEcCtD
L-DOPA—Abdominal pain—Losartan—coronary artery disease	8.03e-05	0.000298	CcSEcCtD
L-DOPA—Asthenia—Captopril—coronary artery disease	8e-05	0.000297	CcSEcCtD
L-DOPA—Diarrhoea—Trandolapril—coronary artery disease	7.98e-05	0.000297	CcSEcCtD
L-DOPA—Vomiting—Valsartan—coronary artery disease	7.98e-05	0.000296	CcSEcCtD
L-DOPA—Confusional state—Lisinopril—coronary artery disease	7.96e-05	0.000296	CcSEcCtD
L-DOPA—Diarrhoea—Enalapril—coronary artery disease	7.95e-05	0.000295	CcSEcCtD
L-DOPA—Hypotension—Timolol—coronary artery disease	7.95e-05	0.000295	CcSEcCtD
L-DOPA—Dizziness—Pravastatin—coronary artery disease	7.95e-05	0.000295	CcSEcCtD
L-DOPA—Vomiting—Olmesartan—coronary artery disease	7.94e-05	0.000295	CcSEcCtD
L-DOPA—Rash—Valsartan—coronary artery disease	7.91e-05	0.000294	CcSEcCtD
L-DOPA—Dermatitis—Valsartan—coronary artery disease	7.91e-05	0.000294	CcSEcCtD
L-DOPA—Nausea—Simvastatin—coronary artery disease	7.9e-05	0.000293	CcSEcCtD
L-DOPA—Oedema—Lisinopril—coronary artery disease	7.89e-05	0.000293	CcSEcCtD
L-DOPA—Pruritus—Captopril—coronary artery disease	7.89e-05	0.000293	CcSEcCtD
L-DOPA—Rash—Olmesartan—coronary artery disease	7.88e-05	0.000293	CcSEcCtD
L-DOPA—Insomnia—Ramipril—coronary artery disease	7.87e-05	0.000292	CcSEcCtD
L-DOPA—Dermatitis—Olmesartan—coronary artery disease	7.87e-05	0.000292	CcSEcCtD
L-DOPA—Headache—Valsartan—coronary artery disease	7.86e-05	0.000292	CcSEcCtD
L-DOPA—Diarrhoea—Telmisartan—coronary artery disease	7.84e-05	0.000291	CcSEcCtD
L-DOPA—Headache—Olmesartan—coronary artery disease	7.83e-05	0.000291	CcSEcCtD
L-DOPA—Paraesthesia—Ramipril—coronary artery disease	7.82e-05	0.00029	CcSEcCtD
L-DOPA—Shock—Lisinopril—coronary artery disease	7.77e-05	0.000288	CcSEcCtD
L-DOPA—Asthenia—Perindopril—coronary artery disease	7.77e-05	0.000288	CcSEcCtD
L-DOPA—Dyspnoea—Ramipril—coronary artery disease	7.76e-05	0.000288	CcSEcCtD
L-DOPA—Vomiting—Niacin—coronary artery disease	7.76e-05	0.000288	CcSEcCtD
L-DOPA—Hypersensitivity—Furosemide—coronary artery disease	7.75e-05	0.000288	CcSEcCtD
L-DOPA—Somnolence—Ramipril—coronary artery disease	7.74e-05	0.000287	CcSEcCtD
L-DOPA—Thrombocytopenia—Lisinopril—coronary artery disease	7.73e-05	0.000287	CcSEcCtD
L-DOPA—Dizziness—Trandolapril—coronary artery disease	7.72e-05	0.000287	CcSEcCtD
L-DOPA—Insomnia—Timolol—coronary artery disease	7.7e-05	0.000286	CcSEcCtD
L-DOPA—Rash—Niacin—coronary artery disease	7.7e-05	0.000286	CcSEcCtD
L-DOPA—Dermatitis—Niacin—coronary artery disease	7.69e-05	0.000286	CcSEcCtD
L-DOPA—Dizziness—Enalapril—coronary artery disease	7.69e-05	0.000285	CcSEcCtD
L-DOPA—Dyspepsia—Ramipril—coronary artery disease	7.66e-05	0.000285	CcSEcCtD
L-DOPA—Pruritus—Perindopril—coronary artery disease	7.66e-05	0.000284	CcSEcCtD
L-DOPA—Headache—Niacin—coronary artery disease	7.65e-05	0.000284	CcSEcCtD
L-DOPA—Paraesthesia—Timolol—coronary artery disease	7.64e-05	0.000284	CcSEcCtD
L-DOPA—Vomiting—Pravastatin—coronary artery disease	7.64e-05	0.000284	CcSEcCtD
L-DOPA—Hyperhidrosis—Lisinopril—coronary artery disease	7.63e-05	0.000283	CcSEcCtD
L-DOPA—Diarrhoea—Captopril—coronary artery disease	7.63e-05	0.000283	CcSEcCtD
L-DOPA—Dyspnoea—Timolol—coronary artery disease	7.59e-05	0.000282	CcSEcCtD
L-DOPA—Dizziness—Telmisartan—coronary artery disease	7.58e-05	0.000282	CcSEcCtD
L-DOPA—Rash—Pravastatin—coronary artery disease	7.58e-05	0.000281	CcSEcCtD
L-DOPA—Dermatitis—Pravastatin—coronary artery disease	7.57e-05	0.000281	CcSEcCtD
L-DOPA—Decreased appetite—Ramipril—coronary artery disease	7.57e-05	0.000281	CcSEcCtD
L-DOPA—Somnolence—Timolol—coronary artery disease	7.57e-05	0.000281	CcSEcCtD
L-DOPA—Asthenia—Furosemide—coronary artery disease	7.55e-05	0.00028	CcSEcCtD
L-DOPA—Headache—Pravastatin—coronary artery disease	7.53e-05	0.00028	CcSEcCtD
L-DOPA—Anorexia—Lisinopril—coronary artery disease	7.53e-05	0.000279	CcSEcCtD
L-DOPA—Gastrointestinal disorder—Ramipril—coronary artery disease	7.52e-05	0.000279	CcSEcCtD
L-DOPA—Fatigue—Ramipril—coronary artery disease	7.51e-05	0.000279	CcSEcCtD
L-DOPA—Dyspepsia—Timolol—coronary artery disease	7.49e-05	0.000278	CcSEcCtD
L-DOPA—Hypersensitivity—Losartan—coronary artery disease	7.48e-05	0.000278	CcSEcCtD
L-DOPA—Nausea—Valsartan—coronary artery disease	7.46e-05	0.000277	CcSEcCtD
L-DOPA—Pruritus—Furosemide—coronary artery disease	7.44e-05	0.000276	CcSEcCtD
L-DOPA—Constipation—Ramipril—coronary artery disease	7.44e-05	0.000276	CcSEcCtD
L-DOPA—Nausea—Olmesartan—coronary artery disease	7.42e-05	0.000276	CcSEcCtD
L-DOPA—Vomiting—Trandolapril—coronary artery disease	7.42e-05	0.000276	CcSEcCtD
L-DOPA—Diarrhoea—Perindopril—coronary artery disease	7.41e-05	0.000275	CcSEcCtD
L-DOPA—Liothyronine—ALB—coronary artery disease	7.4e-05	0.0113	CrCbGaD
L-DOPA—Decreased appetite—Timolol—coronary artery disease	7.4e-05	0.000275	CcSEcCtD
L-DOPA—Vomiting—Enalapril—coronary artery disease	7.39e-05	0.000274	CcSEcCtD
L-DOPA—Hypotension—Lisinopril—coronary artery disease	7.38e-05	0.000274	CcSEcCtD
L-DOPA—Dizziness—Captopril—coronary artery disease	7.37e-05	0.000274	CcSEcCtD
L-DOPA—Rash—Trandolapril—coronary artery disease	7.36e-05	0.000273	CcSEcCtD
L-DOPA—Dermatitis—Trandolapril—coronary artery disease	7.35e-05	0.000273	CcSEcCtD
L-DOPA—Gastrointestinal disorder—Timolol—coronary artery disease	7.35e-05	0.000273	CcSEcCtD
L-DOPA—Fatigue—Timolol—coronary artery disease	7.34e-05	0.000272	CcSEcCtD
L-DOPA—Rash—Enalapril—coronary artery disease	7.33e-05	0.000272	CcSEcCtD
L-DOPA—Dermatitis—Enalapril—coronary artery disease	7.32e-05	0.000272	CcSEcCtD
L-DOPA—Headache—Trandolapril—coronary artery disease	7.31e-05	0.000272	CcSEcCtD
L-DOPA—Vomiting—Telmisartan—coronary artery disease	7.29e-05	0.000271	CcSEcCtD
L-DOPA—Asthenia—Losartan—coronary artery disease	7.28e-05	0.000271	CcSEcCtD
L-DOPA—Headache—Enalapril—coronary artery disease	7.28e-05	0.00027	CcSEcCtD
L-DOPA—Pain—Timolol—coronary artery disease	7.28e-05	0.00027	CcSEcCtD
L-DOPA—Nausea—Niacin—coronary artery disease	7.25e-05	0.000269	CcSEcCtD
L-DOPA—Rash—Telmisartan—coronary artery disease	7.23e-05	0.000268	CcSEcCtD
L-DOPA—Dermatitis—Telmisartan—coronary artery disease	7.22e-05	0.000268	CcSEcCtD
L-DOPA—Diarrhoea—Furosemide—coronary artery disease	7.2e-05	0.000267	CcSEcCtD
L-DOPA—Pruritus—Losartan—coronary artery disease	7.18e-05	0.000267	CcSEcCtD
L-DOPA—Headache—Telmisartan—coronary artery disease	7.18e-05	0.000267	CcSEcCtD
L-DOPA—Feeling abnormal—Ramipril—coronary artery disease	7.17e-05	0.000266	CcSEcCtD
L-DOPA—Dizziness—Perindopril—coronary artery disease	7.16e-05	0.000266	CcSEcCtD
L-DOPA—Insomnia—Lisinopril—coronary artery disease	7.14e-05	0.000265	CcSEcCtD
L-DOPA—Nausea—Pravastatin—coronary artery disease	7.14e-05	0.000265	CcSEcCtD
L-DOPA—Gastrointestinal pain—Ramipril—coronary artery disease	7.12e-05	0.000264	CcSEcCtD
L-DOPA—Paraesthesia—Lisinopril—coronary artery disease	7.09e-05	0.000263	CcSEcCtD
L-DOPA—Vomiting—Captopril—coronary artery disease	7.09e-05	0.000263	CcSEcCtD
L-DOPA—Dyspnoea—Lisinopril—coronary artery disease	7.04e-05	0.000261	CcSEcCtD
L-DOPA—Rash—Captopril—coronary artery disease	7.03e-05	0.000261	CcSEcCtD
L-DOPA—Dermatitis—Captopril—coronary artery disease	7.02e-05	0.000261	CcSEcCtD
L-DOPA—Somnolence—Lisinopril—coronary artery disease	7.02e-05	0.000261	CcSEcCtD
L-DOPA—Feeling abnormal—Timolol—coronary artery disease	7.01e-05	0.00026	CcSEcCtD
L-DOPA—Headache—Captopril—coronary artery disease	6.98e-05	0.000259	CcSEcCtD
L-DOPA—Gastrointestinal pain—Timolol—coronary artery disease	6.96e-05	0.000258	CcSEcCtD
L-DOPA—Dizziness—Furosemide—coronary artery disease	6.96e-05	0.000258	CcSEcCtD
L-DOPA—Dyspepsia—Lisinopril—coronary artery disease	6.95e-05	0.000258	CcSEcCtD
L-DOPA—Diarrhoea—Losartan—coronary artery disease	6.95e-05	0.000258	CcSEcCtD
L-DOPA—Nausea—Trandolapril—coronary artery disease	6.93e-05	0.000257	CcSEcCtD
L-DOPA—Urticaria—Ramipril—coronary artery disease	6.92e-05	0.000257	CcSEcCtD
L-DOPA—Nausea—Enalapril—coronary artery disease	6.9e-05	0.000256	CcSEcCtD
L-DOPA—Vomiting—Perindopril—coronary artery disease	6.88e-05	0.000256	CcSEcCtD
L-DOPA—Abdominal pain—Ramipril—coronary artery disease	6.88e-05	0.000256	CcSEcCtD
L-DOPA—Decreased appetite—Lisinopril—coronary artery disease	6.86e-05	0.000255	CcSEcCtD
L-DOPA—Rash—Perindopril—coronary artery disease	6.82e-05	0.000253	CcSEcCtD
L-DOPA—Dermatitis—Perindopril—coronary artery disease	6.82e-05	0.000253	CcSEcCtD
L-DOPA—Gastrointestinal disorder—Lisinopril—coronary artery disease	6.82e-05	0.000253	CcSEcCtD
L-DOPA—Nausea—Telmisartan—coronary artery disease	6.81e-05	0.000253	CcSEcCtD
L-DOPA—Fatigue—Lisinopril—coronary artery disease	6.81e-05	0.000253	CcSEcCtD
L-DOPA—Headache—Perindopril—coronary artery disease	6.78e-05	0.000252	CcSEcCtD
L-DOPA—Urticaria—Timolol—coronary artery disease	6.76e-05	0.000251	CcSEcCtD
L-DOPA—Constipation—Lisinopril—coronary artery disease	6.75e-05	0.000251	CcSEcCtD
L-DOPA—Pain—Lisinopril—coronary artery disease	6.75e-05	0.000251	CcSEcCtD
L-DOPA—Abdominal pain—Timolol—coronary artery disease	6.73e-05	0.00025	CcSEcCtD
L-DOPA—Dizziness—Losartan—coronary artery disease	6.71e-05	0.000249	CcSEcCtD
L-DOPA—Vomiting—Furosemide—coronary artery disease	6.69e-05	0.000248	CcSEcCtD
L-DOPA—Rash—Furosemide—coronary artery disease	6.63e-05	0.000246	CcSEcCtD
L-DOPA—Dermatitis—Furosemide—coronary artery disease	6.63e-05	0.000246	CcSEcCtD
L-DOPA—Nausea—Captopril—coronary artery disease	6.62e-05	0.000246	CcSEcCtD
L-DOPA—Headache—Furosemide—coronary artery disease	6.59e-05	0.000245	CcSEcCtD
L-DOPA—Feeling abnormal—Lisinopril—coronary artery disease	6.51e-05	0.000242	CcSEcCtD
L-DOPA—Gastrointestinal pain—Lisinopril—coronary artery disease	6.46e-05	0.00024	CcSEcCtD
L-DOPA—Vomiting—Losartan—coronary artery disease	6.46e-05	0.00024	CcSEcCtD
L-DOPA—Nausea—Perindopril—coronary artery disease	6.43e-05	0.000239	CcSEcCtD
L-DOPA—Hypersensitivity—Ramipril—coronary artery disease	6.41e-05	0.000238	CcSEcCtD
L-DOPA—Rash—Losartan—coronary artery disease	6.4e-05	0.000238	CcSEcCtD
L-DOPA—Dermatitis—Losartan—coronary artery disease	6.4e-05	0.000238	CcSEcCtD
L-DOPA—Headache—Losartan—coronary artery disease	6.36e-05	0.000236	CcSEcCtD
L-DOPA—Urticaria—Lisinopril—coronary artery disease	6.27e-05	0.000233	CcSEcCtD
L-DOPA—Hypersensitivity—Timolol—coronary artery disease	6.27e-05	0.000233	CcSEcCtD
L-DOPA—Nausea—Furosemide—coronary artery disease	6.25e-05	0.000232	CcSEcCtD
L-DOPA—Asthenia—Ramipril—coronary artery disease	6.25e-05	0.000232	CcSEcCtD
L-DOPA—Abdominal pain—Lisinopril—coronary artery disease	6.24e-05	0.000232	CcSEcCtD
L-DOPA—Pruritus—Ramipril—coronary artery disease	6.16e-05	0.000229	CcSEcCtD
L-DOPA—Asthenia—Timolol—coronary artery disease	6.11e-05	0.000227	CcSEcCtD
L-DOPA—Nausea—Losartan—coronary artery disease	6.03e-05	0.000224	CcSEcCtD
L-DOPA—Pruritus—Timolol—coronary artery disease	6.02e-05	0.000224	CcSEcCtD
L-DOPA—Diarrhoea—Ramipril—coronary artery disease	5.96e-05	0.000221	CcSEcCtD
L-DOPA—Diarrhoea—Timolol—coronary artery disease	5.82e-05	0.000216	CcSEcCtD
L-DOPA—Hypersensitivity—Lisinopril—coronary artery disease	5.82e-05	0.000216	CcSEcCtD
L-DOPA—Dizziness—Ramipril—coronary artery disease	5.76e-05	0.000214	CcSEcCtD
L-DOPA—Asthenia—Lisinopril—coronary artery disease	5.66e-05	0.00021	CcSEcCtD
L-DOPA—Dizziness—Timolol—coronary artery disease	5.63e-05	0.000209	CcSEcCtD
L-DOPA—Pruritus—Lisinopril—coronary artery disease	5.59e-05	0.000207	CcSEcCtD
L-DOPA—Vomiting—Ramipril—coronary artery disease	5.53e-05	0.000206	CcSEcCtD
L-DOPA—Rash—Ramipril—coronary artery disease	5.49e-05	0.000204	CcSEcCtD
L-DOPA—Dermatitis—Ramipril—coronary artery disease	5.48e-05	0.000204	CcSEcCtD
L-DOPA—Headache—Ramipril—coronary artery disease	5.45e-05	0.000203	CcSEcCtD
L-DOPA—Vomiting—Timolol—coronary artery disease	5.41e-05	0.000201	CcSEcCtD
L-DOPA—Diarrhoea—Lisinopril—coronary artery disease	5.4e-05	0.000201	CcSEcCtD
L-DOPA—Rash—Timolol—coronary artery disease	5.37e-05	0.000199	CcSEcCtD
L-DOPA—Dermatitis—Timolol—coronary artery disease	5.36e-05	0.000199	CcSEcCtD
L-DOPA—Headache—Timolol—coronary artery disease	5.33e-05	0.000198	CcSEcCtD
L-DOPA—Dizziness—Lisinopril—coronary artery disease	5.22e-05	0.000194	CcSEcCtD
L-DOPA—Nausea—Ramipril—coronary artery disease	5.17e-05	0.000192	CcSEcCtD
L-DOPA—Nausea—Timolol—coronary artery disease	5.06e-05	0.000188	CcSEcCtD
L-DOPA—Vomiting—Lisinopril—coronary artery disease	5.02e-05	0.000186	CcSEcCtD
L-DOPA—Rash—Lisinopril—coronary artery disease	4.98e-05	0.000185	CcSEcCtD
L-DOPA—Dermatitis—Lisinopril—coronary artery disease	4.97e-05	0.000185	CcSEcCtD
L-DOPA—Headache—Lisinopril—coronary artery disease	4.95e-05	0.000184	CcSEcCtD
L-DOPA—Nausea—Lisinopril—coronary artery disease	4.69e-05	0.000174	CcSEcCtD
L-DOPA—DRD4—Signaling Pathways—APOA1—coronary artery disease	5.51e-06	3.5e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—POMC—coronary artery disease	5.51e-06	3.5e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—CREB1—coronary artery disease	5.51e-06	3.5e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—JAK2—coronary artery disease	5.5e-06	3.49e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—AGTR1—coronary artery disease	5.5e-06	3.49e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—KDR—coronary artery disease	5.46e-06	3.47e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—DCN—coronary artery disease	5.45e-06	3.46e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—PRKCD—coronary artery disease	5.44e-06	3.45e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—MAPK14—coronary artery disease	5.43e-06	3.44e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—HTR2A—coronary artery disease	5.4e-06	3.43e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—CCL2—coronary artery disease	5.39e-06	3.42e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—C3—coronary artery disease	5.39e-06	3.42e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—PIK3CA—coronary artery disease	5.39e-06	3.42e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—IL6R—coronary artery disease	5.38e-06	3.41e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CXCL10—coronary artery disease	5.37e-06	3.41e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—PLG—coronary artery disease	5.36e-06	3.4e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—HTR2A—coronary artery disease	5.33e-06	3.38e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—ESR1—coronary artery disease	5.32e-06	3.38e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—C3—coronary artery disease	5.32e-06	3.38e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—ALDH2—coronary artery disease	5.3e-06	3.37e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—F2—coronary artery disease	5.26e-06	3.34e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—FN1—coronary artery disease	5.26e-06	3.34e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—IL6ST—coronary artery disease	5.24e-06	3.32e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—ADRB2—coronary artery disease	5.22e-06	3.31e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—NFKBIA—coronary artery disease	5.2e-06	3.3e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—PIK3C2A—coronary artery disease	5.17e-06	3.28e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—LIPC—coronary artery disease	5.17e-06	3.28e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—CYP2C19—coronary artery disease	5.17e-06	3.28e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—HBA1—coronary artery disease	5.17e-06	3.28e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—PRKCE—coronary artery disease	5.15e-06	3.27e-05	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—JAK2—coronary artery disease	5.14e-06	3.26e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—HIF1A—coronary artery disease	5.14e-06	3.26e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—APOC3—coronary artery disease	5.14e-06	3.26e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—SOCS1—coronary artery disease	5.14e-06	3.26e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—AGT—coronary artery disease	5.12e-06	3.25e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—S100B—coronary artery disease	5.12e-06	3.25e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—LDLR—coronary artery disease	5.11e-06	3.24e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—HIF1A—coronary artery disease	5.07e-06	3.22e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—SOCS3—coronary artery disease	5.07e-06	3.22e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—AGT—coronary artery disease	5.06e-06	3.21e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—SLC9A1—coronary artery disease	5.05e-06	3.2e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—GSTT1—coronary artery disease	5.05e-06	3.2e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—KIT—coronary artery disease	5.03e-06	3.19e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—CXCL8—coronary artery disease	5.02e-06	3.19e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—LEP—coronary artery disease	5.02e-06	3.19e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—APOE—coronary artery disease	5.02e-06	3.19e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—TGFBR2—coronary artery disease	5.01e-06	3.18e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—KITLG—coronary artery disease	5.01e-06	3.18e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—CETP—coronary artery disease	4.99e-06	3.16e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—GCLC—coronary artery disease	4.99e-06	3.16e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—APOA1—coronary artery disease	4.96e-06	3.15e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—LEP—coronary artery disease	4.95e-06	3.14e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—APOE—coronary artery disease	4.95e-06	3.14e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—SDC1—coronary artery disease	4.93e-06	3.13e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—KDR—coronary artery disease	4.92e-06	3.12e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—STAT5A—coronary artery disease	4.9e-06	3.11e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—MMP3—coronary artery disease	4.9e-06	3.11e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—APOA1—coronary artery disease	4.9e-06	3.11e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—MAPK14—coronary artery disease	4.89e-06	3.1e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—KDR—coronary artery disease	4.85e-06	3.08e-05	CbGpPWpGaD
L-DOPA—DRD5—GPCR downstream signaling—AKT1—coronary artery disease	4.85e-06	3.08e-05	CbGpPWpGaD
L-DOPA—DDC—Metabolism—PIK3CA—coronary artery disease	4.85e-06	3.08e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—GSK3B—coronary artery disease	4.83e-06	3.06e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—MAPK14—coronary artery disease	4.82e-06	3.06e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—CASP3—coronary artery disease	4.81e-06	3.05e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—ESR1—coronary artery disease	4.79e-06	3.04e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—POMC—coronary artery disease	4.79e-06	3.04e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—CREB1—coronary artery disease	4.79e-06	3.04e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—IL6—coronary artery disease	4.77e-06	3.03e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—APOB—coronary artery disease	4.74e-06	3e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—FN1—coronary artery disease	4.73e-06	3e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—F2—coronary artery disease	4.73e-06	3e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—ESR1—coronary artery disease	4.73e-06	3e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—IL6ST—coronary artery disease	4.72e-06	2.99e-05	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—CXCL8—coronary artery disease	4.7e-06	2.98e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—CCL2—coronary artery disease	4.69e-06	2.97e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—NFKBIA—coronary artery disease	4.68e-06	2.97e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—CCND1—coronary artery disease	4.68e-06	2.97e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—IL6R—coronary artery disease	4.67e-06	2.96e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—JAK2—coronary artery disease	4.67e-06	2.96e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—F2—coronary artery disease	4.67e-06	2.96e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—FN1—coronary artery disease	4.67e-06	2.96e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—EDN1—coronary artery disease	4.66e-06	2.96e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—PSMB5—coronary artery disease	4.66e-06	2.96e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—PSMA6—coronary artery disease	4.66e-06	2.96e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—IL6ST—coronary artery disease	4.65e-06	2.95e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CCL5—coronary artery disease	4.62e-06	2.93e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—NFKBIA—coronary artery disease	4.62e-06	2.93e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—IGF1—coronary artery disease	4.61e-06	2.92e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—MAPK1—coronary artery disease	4.59e-06	2.91e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—FGF1—coronary artery disease	4.55e-06	2.89e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CSF2—coronary artery disease	4.55e-06	2.89e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—CTGF—coronary artery disease	4.55e-06	2.89e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—MMP9—coronary artery disease	4.54e-06	2.88e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—KIT—coronary artery disease	4.53e-06	2.87e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—LPL—coronary artery disease	4.52e-06	2.87e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—GOT2—coronary artery disease	4.51e-06	2.86e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—HMGCR—coronary artery disease	4.51e-06	2.86e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—MEF2C—coronary artery disease	4.48e-06	2.84e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—RPS6KB1—coronary artery disease	4.48e-06	2.84e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—KIT—coronary artery disease	4.47e-06	2.84e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—AKT1—coronary artery disease	4.4e-06	2.79e-05	CbGpPWpGaD
L-DOPA—DRD4—GPCR downstream signaling—PIK3CA—coronary artery disease	4.38e-06	2.78e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—SERPINE1—coronary artery disease	4.38e-06	2.78e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—ITGB3—coronary artery disease	4.37e-06	2.77e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—GSK3B—coronary artery disease	4.35e-06	2.76e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—POMC—coronary artery disease	4.31e-06	2.74e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—CREB1—coronary artery disease	4.31e-06	2.74e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—GSK3B—coronary artery disease	4.29e-06	2.72e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—CXCL8—coronary artery disease	4.26e-06	2.71e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—POMC—coronary artery disease	4.26e-06	2.7e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—CREB1—coronary artery disease	4.26e-06	2.7e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—PPP2CA—coronary artery disease	4.24e-06	2.69e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—FGF2—coronary artery disease	4.24e-06	2.69e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—CCL2—coronary artery disease	4.22e-06	2.68e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—IL6R—coronary artery disease	4.21e-06	2.67e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—NOS3—coronary artery disease	4.18e-06	2.65e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—PRKCD—coronary artery disease	4.17e-06	2.64e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—CCL2—coronary artery disease	4.16e-06	2.64e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—IL6R—coronary artery disease	4.15e-06	2.63e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—IGF1—coronary artery disease	4.15e-06	2.63e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—PLCB1—coronary artery disease	4.15e-06	2.63e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—MAPK1—coronary artery disease	4.13e-06	2.62e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—IGF1—coronary artery disease	4.09e-06	2.6e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—VEGFA—coronary artery disease	4.08e-06	2.59e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—HTR2A—coronary artery disease	4.08e-06	2.59e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—MAPK1—coronary artery disease	4.07e-06	2.58e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—C3—coronary artery disease	4.07e-06	2.58e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—JAK2—coronary artery disease	4.06e-06	2.58e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—ABCA1—coronary artery disease	4.02e-06	2.55e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—PIK3CA—coronary artery disease	3.98e-06	2.52e-05	CbGpPWpGaD
L-DOPA—DDC—Metabolism—AKT1—coronary artery disease	3.96e-06	2.51e-05	CbGpPWpGaD
L-DOPA—DRD1—GPCR downstream signaling—PIK3CA—coronary artery disease	3.94e-06	2.5e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—SERPINE1—coronary artery disease	3.94e-06	2.5e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—GGT1—coronary artery disease	3.89e-06	2.47e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—GOT1—coronary artery disease	3.89e-06	2.47e-05	CbGpPWpGaD
L-DOPA—DRD3—GPCR downstream signaling—PIK3CA—coronary artery disease	3.89e-06	2.47e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—SERPINE1—coronary artery disease	3.89e-06	2.47e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—HIF1A—coronary artery disease	3.88e-06	2.46e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—AGT—coronary artery disease	3.87e-06	2.45e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—FGF2—coronary artery disease	3.81e-06	2.42e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—LEP—coronary artery disease	3.79e-06	2.4e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—APOE—coronary artery disease	3.79e-06	2.4e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—FGF2—coronary artery disease	3.76e-06	2.39e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—NOS3—coronary artery disease	3.76e-06	2.39e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—APOA1—coronary artery disease	3.75e-06	2.38e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—TGFB1—coronary artery disease	3.74e-06	2.37e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—KDR—coronary artery disease	3.71e-06	2.36e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—NOS3—coronary artery disease	3.71e-06	2.35e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—CXCL8—coronary artery disease	3.71e-06	2.35e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—MAPK14—coronary artery disease	3.69e-06	2.34e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—MAPK1—coronary artery disease	3.67e-06	2.33e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—JAK2—coronary artery disease	3.66e-06	2.32e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—ESR1—coronary artery disease	3.62e-06	2.3e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—JAK2—coronary artery disease	3.61e-06	2.29e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—PIK3CA—coronary artery disease	3.58e-06	2.27e-05	CbGpPWpGaD
L-DOPA—DRD4—GPCR downstream signaling—AKT1—coronary artery disease	3.58e-06	2.27e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—F2—coronary artery disease	3.57e-06	2.27e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—FN1—coronary artery disease	3.57e-06	2.27e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—IL6ST—coronary artery disease	3.56e-06	2.26e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—CASP3—coronary artery disease	3.55e-06	2.25e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—PIK3CA—coronary artery disease	3.53e-06	2.24e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—NFKBIA—coronary artery disease	3.53e-06	2.24e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—IL6—coronary artery disease	3.52e-06	2.24e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—GSTP1—coronary artery disease	3.5e-06	2.22e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—PPARGC1A—coronary artery disease	3.46e-06	2.2e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—CCND1—coronary artery disease	3.45e-06	2.19e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—HMOX1—coronary artery disease	3.45e-06	2.19e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—KIT—coronary artery disease	3.42e-06	2.17e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—CAT—coronary artery disease	3.4e-06	2.16e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—MMP9—coronary artery disease	3.35e-06	2.13e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—CXCL8—coronary artery disease	3.34e-06	2.12e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—APOB—coronary artery disease	3.3e-06	2.1e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—CXCL8—coronary artery disease	3.29e-06	2.09e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—GSK3B—coronary artery disease	3.28e-06	2.08e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—POMC—coronary artery disease	3.26e-06	2.07e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CREB1—coronary artery disease	3.26e-06	2.07e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—AKT1—coronary artery disease	3.25e-06	2.06e-05	CbGpPWpGaD
L-DOPA—DRD1—GPCR downstream signaling—AKT1—coronary artery disease	3.22e-06	2.04e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—GSTM1—coronary artery disease	3.21e-06	2.04e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—CASP3—coronary artery disease	3.19e-06	2.03e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CCL2—coronary artery disease	3.19e-06	2.02e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—PIK3CA—coronary artery disease	3.19e-06	2.02e-05	CbGpPWpGaD
L-DOPA—DRD3—GPCR downstream signaling—AKT1—coronary artery disease	3.18e-06	2.02e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—IL6R—coronary artery disease	3.18e-06	2.02e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—IL6—coronary artery disease	3.17e-06	2.01e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—LPL—coronary artery disease	3.15e-06	2e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—CASP3—coronary artery disease	3.15e-06	2e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—IGF1—coronary artery disease	3.13e-06	1.99e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—IL6—coronary artery disease	3.13e-06	1.99e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—MAPK1—coronary artery disease	3.12e-06	1.98e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—CCND1—coronary artery disease	3.11e-06	1.97e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—GPX1—coronary artery disease	3.08e-06	1.95e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—CCND1—coronary artery disease	3.07e-06	1.95e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—MMP9—coronary artery disease	3.02e-06	1.91e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—VEGFA—coronary artery disease	3.01e-06	1.91e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—CD36—coronary artery disease	3e-06	1.9e-05	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—PIK3CA—coronary artery disease	2.98e-06	1.89e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—MMP9—coronary artery disease	2.98e-06	1.89e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—SERPINE1—coronary artery disease	2.97e-06	1.89e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—PPP2CA—coronary artery disease	2.96e-06	1.88e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—AKT1—coronary artery disease	2.93e-06	1.86e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—AKT1—coronary artery disease	2.89e-06	1.83e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—FGF2—coronary artery disease	2.88e-06	1.83e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—MTHFR—coronary artery disease	2.84e-06	1.8e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—NOS3—coronary artery disease	2.84e-06	1.8e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—IL6—coronary artery disease	2.82e-06	1.79e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—TGFB1—coronary artery disease	2.76e-06	1.75e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—JAK2—coronary artery disease	2.76e-06	1.75e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—VEGFA—coronary artery disease	2.71e-06	1.72e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—MAPK1—coronary artery disease	2.71e-06	1.72e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—PIK3CA—coronary artery disease	2.7e-06	1.72e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—AGT—coronary artery disease	2.7e-06	1.71e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—VEGFA—coronary artery disease	2.67e-06	1.7e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—APOE—coronary artery disease	2.64e-06	1.68e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—APOA1—coronary artery disease	2.61e-06	1.66e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—AKT1—coronary artery disease	2.6e-06	1.65e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CXCL8—coronary artery disease	2.52e-06	1.6e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—TGFB1—coronary artery disease	2.49e-06	1.58e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—TGFB1—coronary artery disease	2.45e-06	1.56e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—MAPK1—coronary artery disease	2.44e-06	1.55e-05	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—AKT1—coronary artery disease	2.43e-06	1.54e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CASP3—coronary artery disease	2.41e-06	1.53e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—MAPK1—coronary artery disease	2.41e-06	1.53e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—IL6—coronary artery disease	2.4e-06	1.52e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—PIK3CA—coronary artery disease	2.35e-06	1.49e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CCND1—coronary artery disease	2.35e-06	1.49e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—PPARG—coronary artery disease	2.3e-06	1.46e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—MMP9—coronary artery disease	2.28e-06	1.45e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—POMC—coronary artery disease	2.27e-06	1.44e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—AKT1—coronary artery disease	2.21e-06	1.4e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—PIK3CA—coronary artery disease	2.12e-06	1.34e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—PIK3CA—coronary artery disease	2.09e-06	1.32e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—IL6—coronary artery disease	2.08e-06	1.32e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—ALB—coronary artery disease	2.07e-06	1.31e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—VEGFA—coronary artery disease	2.05e-06	1.3e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—NOS3—coronary artery disease	1.98e-06	1.26e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—AKT1—coronary artery disease	1.92e-06	1.22e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—TGFB1—coronary artery disease	1.88e-06	1.19e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—IL6—coronary artery disease	1.87e-06	1.19e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—IL6—coronary artery disease	1.85e-06	1.17e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—MAPK1—coronary artery disease	1.84e-06	1.17e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—PTGS2—coronary artery disease	1.81e-06	1.15e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—AKT1—coronary artery disease	1.73e-06	1.1e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—AKT1—coronary artery disease	1.71e-06	1.08e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—PIK3CA—coronary artery disease	1.6e-06	1.01e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—IL6—coronary artery disease	1.41e-06	8.98e-06	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—AKT1—coronary artery disease	1.31e-06	8.28e-06	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—PIK3CA—coronary artery disease	1.11e-06	7.07e-06	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—AKT1—coronary artery disease	9.11e-07	5.78e-06	CbGpPWpGaD
